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Despite advances in pharmacotherapy, diabetic kidney disease (DKD) remains associated with a
high burden of micro- and macrovascular complications often leading to premature mortality.
New therapies are highly desirable to mitigate the burden of this disease. However, there are a
number of barriers that hamper drug development in DKD. These include, amongst others, the
lengthy and complex clinical trials required to prove drug efficacy and safety, inefficiencies in
clinical trial conduct, and the high costs associated with these development programs. In this
review a number of aspects are discussed, aiming to identify opportunities to transform and
innovate drug development for DKD. Many clinical trials in DKD, as well as in other areas, face
difficulties in timely and efficient enrolment of participants. To address this issue a network of
sites should be created that are continuously recruiting individuals with DKD and collecting cru-
cial information that can be used to understand prognosis and prognostic factors, and more
importantly to serve as a pool of participants for recruitment to randomized trials. Second, the
current clinical endpoints are late events in the progression of DKD. Endpoints based on lesser
declines in estimated glomerular filtration rate (eGFR) or changes in albuminuria can shorten
follow-up and/or lead to smaller and cheaper trials. Enrichment by enrolling clinical trial popula-
tions based on biomarker profiles is another approach that may facilitate clinical trial efficiency
and conduct. Biomarkers can be used to individualize treatment by targeting populations more
likely to respond leading to smaller and more efficient trials. Finally, using new trial design such
as basket, umbrella or more broadly platform trials to assess a number of therapies simulta-
neously offers the potential to transform the drug development process in DKD. There are a
number of opportunities to transform development approaches for new therapies for DKD.
Platform trials along with appropriate biomarker-based enrichment strategies offer the possibil-
ity to foster drug development in a precision medicine era.
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1 | INTRODUCTION
With the global epidemic of obesity has come an epidemic of
downstream manifestations, including rising rates of diabetic kidney
disease (DKD).1 Roughly 450 million adults worldwide have diabe-
tes, and more than a third of them will develop chronic kidney dis-
ease.2 The condition is relentlessly progressive, leading to
significant morbidity and mortality, both from increased cardiovas-
cular disease burden and from end-stage renal disease (ESRD) and
its complications.
The economic impact of DKD to healthcare systems is enormous as
well. For example, annual per patient healthcare expenditures for hemo-
dialysis exceed $80 000 in the United States,3 and €50 000 in Germany.4
These costs exceed the wherewithal of many developing countries, and
as a result the worldwide need for renal replacement therapy exceeds
capacity,5 leaving many without access to this life-extending therapy.
Beyond the obvious need to stem the underlying obesity and dia-
betes epidemics, there is a need for new medicines to treat mild to
moderate renal impairment, where the opportunity to halt or slow dis-
ease progression can meaningfully impact quality and quantity of life.
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Current strategies for delaying progression of DKD are based around
risk factor reduction—primarily blood sugar and blood pressure
control—and angiotensin converting enzyme (ACE) inhibitor or angio-
tensin receptor blocker therapy.6,7 It has been decades since a new
class of medicines was introduced to delay disease progression. Indeed,
investment in DKD research and drug development has not kept pace
with the rising prevalence of the disease, and the number of random-
ized controlled trials in this area lags far behind other disease areas.
Currently, there are only three new drugs being tested in phase 3 trials.
The lack of a robust pipeline of new therapeutics in development
is compounded by the relative homogeneity of the available mecha-
nisms. All agents approved or in late development work in part if not
entirely through alterations of renal hemodynamics and glomerular
pressure. There is a gap in new medicines that take an orthogonal
approach, addressing targets specific to the tubulointerstitial inflam-
matory and fibrotic components of the disease. A rapid increase over
the past two decades in our understanding of the immune system has
led to an explosion of therapies for disorders ranging from rheumatoid
arthritis to lung cancer, but this growth in scientific knowledge has yet
to be translated to the treatment of DKD.
The relative paucity of innovation in DKD can be traced directly
to the high barrier to entry in this space. Clinical trials in DKD are
lengthy and expensive. A phase 3 trial typically takes more than
5 years to conduct. Time is needed to observe patients long enough
to show a separation of estimated glomerular filtration rate (eGFR)
curves between study arms, and a sizable number of patients must
progress to ESRD or death for a study to be considered to constitute
adequate registrational evidence, a lengthy undertaking. Finally, for a
trial to be sufficiently powered requires the participation of thousands
of patients, a size that can take years, by standard metrics, to recruit.
Operational inefficiencies add to the timeline. Each program
requires setting up a cooperative framework of sponsor, academic
research organization, steering committee, independent data moni-
toring committee, contract research organization and multiple inves-
tigative sites across countries and continents. This amalgam must
guide the trial through a number of activities that each present
incremental chances for delay, including country-specific regulatory
and institutional review board approval, site selection, contracting,
manufacturing of clinical supplies and obtaining necessary import
licenses. After these steps, a not insignificant proportion of study
sites find themselves unable to live up to overly ambitious recruit-
ment projections, some failing to recruit a single patient over the
course of a study.
All this comes at a cost of hundreds of millions of Euros. Because
phase 3 data in DKD comes in a bolus at the end of large, blinded out-
comes trials, this is an “all in” investment. By way of contrast, in many
other disease areas evidence of efficacy accumulates over smaller,
shorter trials, allowing for multiple decision points for advancing or ter-
minating a program, and thus a lower cost to each next decision point.
In order for there to be a rejuvenation of research and develop-
ment into therapies for DKD we must seek an improvement in the
framework—the time, cost, and complexity—in which we conduct the
clinical trials programs.
2 | ADVANCES IN CLINICAL TRIAL DESIGNS
TO FOSTER DRUG DEVELOPMENT
Given the size of the existing gap between development in DKD and
other therapeutic areas, a multi-pronged, transformative approach is
needed—incremental change will by definition only have a marginal
impact. Innovative approaches are required to address many of the
issues listed above. As a community of researchers working to
improve outcomes for people with diabetes, we must reimagine the
research approach, and develop a new paradigm for clinical trials in
DKD for the 21st century. This means carefully examining all aspects
of our current approach to drug development, and being brave
enough to take a leap forwards. A number of aspects are particularly
important to reassess.
2.1 | Populations and data collection
Currently, the design of clinical trials is finalized often with little input
from the sites where the actual recruitment is to occur. Busy clinicians
at sites interested in participating fill out complex forms, and estimate
the number of trial participants they might be able to recruit. It is
notoriously difficult to integrate the impact of various inclusion and
exclusion criteria and use this information to reliably estimate how
many participants might truly be recruited. As a result, actual recruit-
ment is commonly half or less the number estimated by many sites.
A better model would be to have reliable data regarding the
actual number of participants who fulfil proposed inclusion and exclu-
sion criteria. By combining this with an estimate of the proportion of
potential participants who might agree to participate, a more reliable
projection can be made. Being able to do this will require effectively
creating a network of sites that are continuously recruiting individuals
with DKD to a large database after they have consented to participa-
tion, and collecting crucial information that can be used to assess the
impact of specific criteria on recruitment capacity. Effectively, this
would mean the creation of a large, international registry, albeit with
limited data capture. Ideally, this data could then be used to refine the
trial criteria, in an iterative approach that will help optimize design.
This registry has the key additional advantage of offering a ready pool
of potential trial participants for new trials.
A related aspect is collection of data. Current approaches require
replication of demographic, clinical and laboratory data collection, an
approach that has not been shown to be superior to the use of data
that has been collected as part of routine clinical practice. Increased
usage of established data sources is another way efficiency can be
increased dramatically while maintaining reliability. This is particularly
true where data from a range of data sources can be accessed to
ascertain outcomes (eg, dialysis registries) during the course of a trial.
Achieving this goal will require regulatory authority agreement for
reduced reliance on trial-specific data collection instruments and har-
monized central laboratory assessments, and upfront investment to
establish a network and database. If achieved this approach has the
potential to streamline and transform recruitment to clinical trials in
an efficient, low cost fashion.
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2.2 | Endpoints
A key challenge in kidney disease, is that progression is slow, and the
most clinically important endpoints take a long time to develop. This
means that trial event rates may be very low. For example, the
ADVANCE, EMPA-REG and CANVAS trials recruited almost 30 000
people with diabetes at high risk of cardiovascular disease, yet despite
over 100 000 patient years of follow up, fewer than 100 participants
had developed kidney failure requiring dialysis or transplantation or
leading to death. Endpoints based on lesser degrees of loss of kidney
function are therefore of great interest. Doubling of serum creatinine
(loss of 57% of kidney function) is an established endpoint, and more
recent efforts led by the US National Kidney Foundation and regula-
tory agencies assessing lesser degrees of kidney function loss have led
to the use of a 40% loss of kidney function as an endpoint for current
trials.8,9 More recently, the use of eGFR slope and albuminuria has
been explored in a large workshop and offer to further improve feasi-
bility of clinical trials in kidney disease, while maintaining rigor and
reliability.
2.3 | Enrichment approaches to tailor therapy
Another approach to increasing efficiency is to “enrich” the trial popula-
tion. Biomarkers can be used in various ways to enrich clinical trial
populations and individualize treatments. Biomarkers can be used to
enrich for a population at high risk to develop the event of interest, so
called prognostic enrichment. Biomarkers can also be used to enrich for
a population more likely to respond to the drug of interest. These bio-
markers are referred to as predictive or dynamic biomarkers (Figure 1).
Past clinical trials in DKD have enriched the population for
patients at risk of reaching dialysis by including patients with low
eGFR and high albuminuria. However, DKD is a multi-factorial disease
involving various pathophysiological pathways such as endothelial
injury, inflammation and fibrosis that can drive eGFR progression.
Novel biomarkers that capture these pathways may help to identify a
clinical trial population at high risk of progressive kidney function loss
which can reduce clinical trial sample sizes. Recent studies suggest
that tumor necrosis factor-1 and kidney injury molecule-1 may be
suitable for this purpose.10,11 Another ongoing study, the PRIORITY
trial (NCT02040441), uses a panel consisting of 273 peptides to iden-
tify individuals at high risk of developing microalbuminuria. These indi-
viduals are subsequently treated with spironolactone or placebo. The
disadvantage of this risk-based enrichment approach is that the bio-
markers do not provide information if the individual patient is going to
respond to the drug of interest. Theoretically, it is possible that a
high-risk clinical trial population could be selected at such advanced
stages of disease that it would be impossible to reverse or slow dis-
ease progression by pharmacological intervention.
Biomarkers can also be used to identify a population more likely
to respond before exposing the population to the drug of interest.
These so called predictive biomarkers—which can be genes, proteins
or metabolites—are often used in other areas in medicine in particular
oncology. Various gene polymorphisms predict the response to anti-
cancer drugs. For example, lung cancers with a mutant epidermal
growth factor receptor usually respond better to epidermal growth
factor inhibitors.12 Apart from one study reporting that polymor-
phisms in the ACE gene predict the response to angiotensin receptor
blockers in patients with DKD no predictive biomarkers are yet dis-
covered.13 The explanation for the paucity of predictive biomarkers in
diabetes and kidney disease compared to oncology is that underlying
molecular mechanisms are less well described in DKD compared to
oncology and that specific drugs targeting these molecular processes
are not (yet) available.
Perhaps a more useful approach, at least for the time being, to
enrich clinical trials for populations more likely to respond is to expose
the target population for a short-term to the drug of interest. This
approach has actually already been used for decades by using active
run-in periods to identify potential participants who will not tolerate
the intervention soon after commencing it, and therefore are unlikely
to benefit or be harmed by the intervention. The use of active run-in
periods has been employed in lipid (eg, HPS, SHARP) and blood pres-
sure lowering (eg, ADVANCE, ONTARGET) trials.14–16
The same approach can potentially be used to identify trial sub-
populations that might be particularly likely to benefit. This might
include participant characteristics at entry to the trial, or might also
include the effect of the intervention on post-randomization interme-
diate outcomes that are expected to capture the effects of the inter-
vention, and has been an area of interest for regulatory agencies.17
For example, a lipid lowering agent would not be expected to produce
cardiovascular benefit via lipid lowering if it doesn't actually lower
lipids in an individual participant, presuming the effect on the interme-
diate outcome can be accurately captured. Reliably measuring the
effect on intermediate outcomes can be a challenge for parameters







FIGURE 1 Enrichment approaches for patient selection in clinical
trials. Biomarkers can be used to select patients based on risk of
disease progression (baseline risk enrichment; green shaded area),
based on the drug response before exposure (predictive response
enrichment; blue shaded area), or based on the change in a biomarker
after short-term exposure to the drug (dynamic response enrichment;
orange shaded area). The ideal biomarker or set of biomarkers would
capture the three domains
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considered. However, despite the day-to-day variation for some
parameters, it is clear that the effects of at least some interventions
are highly variable at a between individual level.18 This approach has
been used in the recent study of diabetic nephropathy with atransen-
tan (SONAR) trial, where potential participants were exposed to the
endothelin antagonist atrasentan, and those who had a 30% reduction
in albuminuria were considered responders and further random-
ized.19,20 The event rate in this trial was lower than expected,
highlighting the potential risk of unanticipated consequences.21
SONAR also randomized approximately 1000 “non-responders” to the
trial to assess whether responder status truly predicts effects on hard
outcomes. The SONAR results are awaited with interest.
2.4 | Basket and umbrella trials
A further development in clinical trials in other areas of medicine
offers additional opportunities. The use of “basket” or “umbrella” trials,
or more commonly called “platform” trials involves assessing the
effects of multiple interventions on one or more conditions, using
modern adaptive designs and statistical approaches, including Bayes-
ian analyses (Table 1).22,23 A common feature of basket, umbrella and
platform trials is the use of a Master Trial Protocol which defines
overarching clinical trial elements for the various individual trials con-
ducted within the platform with relative minor trial design differences
depending on unique drug characteristics. The master trial protocol
enables sharing of trial documents and procedures across trials sup-
porting trial consistency and efficiency.
The platform trial approach would benefit from a large registry of
patients with diabetes and/or kidney disease who are willing to be
approached about research studies in the future and agree to the col-
lection of a minimal set of clinically available information such as their
diabetes duration, cause of their kidney disease and cardiovascular dis-
ease history. Individual trials would be nested in the registry, recruiting
from the characterized registry participants. Direct access to patients
from the ongoing platform offers a unique opportunity to overcome
recruitment challenges often observed in clinical trials of DKD.
The platform trial approach offers the possibility to implement
personalized medicine in the trial design and future clinical practice.
The availability of multiple interventions within the platform can be
used to successively test patients until they show a biomarker
response to a treatment, at which point they would be randomized to
that treatment or placebo plus standard of care. This enables the
incorporation of the individual therapy response and selection of best
available therapy for each patient thereby paving the way for a tai-
lored/personalized treatment approach.
Platform trials have been established in other areas of medicine
such as oncology, Alzheimer disease and community acquired
pneumonia. For example, the investigation of serial studies to predict
your therapeutic response with Imaging And moLecular analysis 2
platform was established for the evaluation of candidate treatments
for neoadjuvant therapies for biomarker-defined breast cancer.24 Mul-
tiple candidate therapies from individual sponsors are tested within
the structure. The Biomarker-integrated Approaches of Targeted
Therapy for Lung Cancer Elimination (BATTLE) trial is another exam-
ple from the oncology area. This platform utilizes adaptive randomiza-
tion schemes to assign patients to treatment with the greatest
potential based on non-small cell lung cancer tumor markers
(NCT00409968). A diabetes and/or kidney disease platform should
leverage the experience and knowledge gained by these initiatives.
3 | FUTURE CLINICAL TRIALS IN DIABETIC
KIDNEY DISEASE
The opportunity to dramatically change our approach to developing
treatments in DKD exists, using most or all of these new elements. A
network of sites continuously registering consenting patients with
DKD, to a platform assessing a number of interventions simulta-
neously using an adaptive approach, and using the effects on some of
the newly validated outcomes to identify effective interventions could
lead to a paradigm shift in DKD management and outcomes. The addi-
tional use (where appropriate) of routinely collected data sources and
TABLE 1 Terminology for types of master protocols
Type of trial Objective Examples of potential innovative approaches
Umbrella To study multiple targeted therapies in the context
of a single disease
Within a conventionally defined disease (eg, diabetic kidney disease [DKD]),
various biomarker-based subgroups are defined and different drugs are
tested in these subgroups. This approach supports individualizing
treatments and personalized medicine.
Basket To study a single-targeted therapy in the context of
multiple disease or disease subtypes
Many of the potential drug targets in DKD may also be useful for other
etiologies of chronic kidney disease (CKD) such as IgA nephropathy or
focal segmental Glomerulo sclerosis. A basket trial enrolls patients across
various CKD etiologies and characterizes the drug effect in multiple
disorders. This may enhance innovation while allowing sponsors a wider
range of potential indications for a given molecule.
Platform To study multiple-targeted therapies in the context of a
single disease in a perpetual manner, with therapies
allowed to enter or leave the platform on the basis
of a decision algorithm
Platform trials may lower the hurdle to take a new drug forward into a proof
of concept clinical trial because a new molecule could be plugged into an
ongoing clinical trial quickly and at a lower cost. An additional benefit is
that the platform enables characterizing the efficacy and safety of novel
drug combinations, potentially across conditions, mechanisms and
sponsors, that would otherwise not be feasible in one trial. Finally,
within the platform drugs can be targeted to subgroups based on
biomarker profiles to personalize treatment.
Modified from Reference 22.
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enrichment approaches offer to further improve efficiency, to individ-
ualize treatment, and to drive investment in DKD research.
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